Filing Details
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the Securities and Exchange Commission on October 29, 2026, disclosing a material event.
8k filedNASDAQ:PCSA
Processa Pharmaceuticals, Inc. (PCSA) Reports Material Event to SEC
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) filed a Form 8-K with the Securities and Exchange Commission on October 29, 2026, disclosing a material event.
At publication ·
What changed
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Processa Pharmaceuticals filed a Form 8-K on October 29, 2026, disclosing a material event that shareholders should know about.
- The company's stock trades at $1.89 per share with a market capitalization of $15.6 million.
- Material events reported in 8-K filings can include leadership changes, acquisitions, asset sales, or changes to financial guidance.
Market Context
Processa Pharmaceuticals, Inc.'s stock currently trades at $1.89 with a market capitalization of $15.6M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Processa Pharmaceuticals, Inc.'s stock.
All SEC filings for Processa Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PCSA Stock Page
Frequently Asked Questions
Where can I read PCSA's SEC filings?
Browse all filings on our PCSA SEC filings page.
What types of SEC filings does Processa Pharmaceuticals, Inc. file?
Public companies like Processa Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.